Live Breaking News & Updates on ப்ரோடீந் வெளிப்பாடு தொழில்நுட்பம்

Stay updated with breaking news from ப்ரோடீந் வெளிப்பாடு தொழில்நுட்பம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Protein Expression Technology Market comprehensive study by Key Players: NEB, Merck, Cytovance Biologics

Protein Expression Technology Market comprehensive study by Key Players: NEB, Merck, Cytovance Biologics
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , South Africa , Cytovance Biologics , Contract Research Organizations Biotechnological Companies , Academic Research Institutes , Market Development Outlook Study , Global Protein Expression Technology Market Study , Order Global Protein Expression Technology Market , Research Analyst , Market Intelligence Consulting Private , Key Development , Research Newswire , Research Objectives , Protein Expression Technology , Custom Research , Global Protein Expression Technology , Product Service , Global Protein Expression Technology Market Development Scenario , Players By Issuing Office , Global Protein Expression Technology Market , See Campaign , Global Protein Expression Technology Market Intense , Protein Expression Technology Market Competition , Expression Technology , Development Outlook ,

Ligand Reports First Quarter 2021 Financial Results

Ligand Reports First Quarter 2021 Financial Results
Search jobs
Conference Call Begins at 4:30 p.m. Eastern Time Today
SAN DIEGO (BUSINESS WIRE) $LGND#earnings
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
“This year has opened strong for Ligand with solid financial performance and great results from all of our core technology platforms,” said John Higgins, Chief Executive Officer. “We are very pleased to report a smooth and efficient integration of the four acquisitions we closed last year. Our R&D team has expanded considerably and we are reaping the benefits of these transactions with more licensing deals and contract revenue. Working within a highly dynamic and unpredictable COVI ....

John Higgins , Valentino Stella , Jay Gertz , Bruce Voss , Acrotech Biopharma , Baxter International , Jazz Pharmaceuticals , University Of Utah , Pelican Expression Technology , Serum Institute Of India , Cstone Pharmaceuticals , Gilead Sciences , Ligand Pharmaceuticals , Ligand Pharmaceuticals Incorporated , Huntsman Cancer Institute , European Commission , Drug Administration , University Distinguished Professor , Ligand Protein Expression Technology , University Of Kansa Higuchi Biosciences Center , Sermonix Pharmaceuticals , European Medicines Agency , Conference Call Begins , Chief Executive , Recent Business Highlights , Biological Intelligence ,